Xiyong Liu Selected Research

Ribonucleotide Reductases (Ribonucleotide Reductase)

1/2018	Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer.
1/2016	Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
1/2016	The Impact of dUTPase on Ribonucleotide Reductase-Induced Genome Instability in Cancer Cells.
6/2015	The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
9/2014	Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
7/2014	Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients.
1/2014	The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
12/2013	Targeting ribonucleotide reductase for cancer therapy.
6/2013	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
5/2013	Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiyong Liu Research Topics

Disease

40	Neoplasms (Cancer) 11/2020 - 10/2006
17	Breast Neoplasms (Breast Cancer) 11/2020 - 10/2006
7	Neoplasm Metastasis (Metastasis) 02/2019 - 11/2006
6	Carcinogenesis 04/2022 - 11/2006
6	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 04/2011
3	Pancreatic Neoplasms (Pancreatic Cancer) 04/2022 - 03/2016
3	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2019 - 07/2010
3	Hepatocellular Carcinoma (Hepatoma) 02/2015 - 11/2007
2	Gallbladder Neoplasms (Gallbladder Cancer) 03/2016 - 05/2015
2	Genomic Instability 01/2016 - 01/2016
2	Starvation 04/2014 - 11/2005
2	Squamous Cell Carcinoma of Head and Neck 01/2013 - 05/2009
2	Hypoxia (Hypoxemia) 03/2012 - 02/2009
1	Wounds and Injuries (Trauma) 01/2020
1	Adenocarcinoma 01/2020
1	Microcephaly 02/2019
1	Urinary Bladder Neoplasms (Bladder Cancer) 02/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Pathologic Processes 03/2016
1	Liver Neoplasms (Liver Cancer) 03/2016
1	Disease Progression 08/2015
1	Prostatic Neoplasms (Prostate Cancer) 01/2014
1	Hematologic Neoplasms (Hematological Malignancy) 12/2013

Drug/Important Bio-Agent (IBA)

20	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2018 - 10/2006
19	Biomarkers (Surrogate Marker)IBA 11/2020 - 11/2006
15	Proteins (Proteins, Gene)FDA Link 02/2019 - 05/2005
8	Messenger RNA (mRNA)IBA 01/2020 - 05/2009
6	Estrogen ReceptorsIBA 11/2020 - 09/2014
5	Biological ProductsIBA 01/2019 - 05/2013
4	Small Interfering RNA (siRNA)IBA 01/2020 - 02/2009
4	Gemcitabine FDA Link 11/2016 - 03/2006
3	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 01/2007
3	KinesinsIBA 01/2020 - 01/2018
3	MicroRNAs (MicroRNA)IBA 01/2020 - 05/2013
3	Calcibiotic Root Canal SealerIBA 05/2013 - 05/2011
3	Indicators and Reagents (Reagents)IBA 03/2012 - 07/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2009 - 05/2005
2	ribonucleotide reductase M2IBA 04/2022 - 10/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 01/2017
2	VinculinIBA 01/2019 - 08/2015
2	Phosphotransferases (Kinase)IBA 01/2019 - 08/2015
2	Pharmaceutical PreparationsIBA 11/2016 - 06/2015
2	EnzymesIBA 06/2015 - 04/2014
2	Glycoproteins (Glycoprotein)IBA 05/2015 - 10/2012
2	GlypicansIBA 02/2015 - 01/2009
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2015 - 01/2015
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2020
1	Adenosine Triphosphate (ATP)IBA 11/2020
1	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 11/2020
1	DEAD-box RNA HelicasesIBA 01/2020
1	Etoposide (VP 16)FDA LinkGeneric 04/2019
1	Cytoskeletal ProteinsIBA 01/2019
1	TalinIBA 01/2019
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2019
1	Sirolimus (Rapamycin)FDA Link 01/2019
1	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2019
1	karyopherin alpha 2IBA 01/2019
1	TOR Serine-Threonine KinasesIBA 01/2019
1	Mitochondrial Permeability Transition PoreIBA 01/2018
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2018
1	Superoxides (Superoxide)IBA 01/2018
1	Uridine KinaseIBA 06/2017
1	ProdrugsIBA 06/2017
1	delta-1-pyrroline-5-carboxylateIBA 01/2017
1	Oxidoreductases (Dehydrogenase)IBA 01/2017
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2017
1	methylcobalamin-coenzyme M methyltransferaseIBA 11/2016
1	Equilibrative Nucleoside Transporter 1IBA 11/2016
1	Serine (L-Serine)FDA Link 11/2016
1	Hydroxyl RadicalIBA 11/2016
1	Calcium-Binding ProteinsIBA 03/2016
1	S100 Proteins (S 100 Protein)IBA 03/2016
1	Tamoxifen FDA LinkGeneric 01/2016
1	dUTP pyrophosphataseIBA 01/2016
1	CateninsIBA 08/2015
1	HoloenzymesIBA 06/2015
1	AntimetabolitesIBA 06/2015
1	IntegrinsIBA 05/2015
1	Fibronectins (Fibronectin)IBA 05/2015
1	veliparibIBA 01/2015
1	Carboplatin (JM8)FDA LinkGeneric 01/2015
1	Estrogens (Estrogen)FDA Link 09/2014
1	Cytostatic AgentsIBA 04/2014
1	Arginine (L-Arginine)FDA Link 04/2014
1	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 04/2014
1	ADI PEG20IBA 04/2014
1	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 06/2013
1	NF-kappa B (NF-kB)IBA 05/2013
1	TransducinIBA 05/2013
1	Viral ProteinsIBA 05/2013
1	ORALIT (ORS)IBA 05/2013

Therapy/Procedure

9	Therapeutics 01/2019 - 01/2013
8	Drug Therapy (Chemotherapy) 01/2021 - 07/2010
1	Adjuvant Chemotherapy 01/2021
1	Radiotherapy 01/2020
1	Precision Medicine 11/2016